Advertisement
UK markets close in 6 hours 42 minutes

  • FTSE 100

    8,092.80
    +52.42 (+0.65%)
     

  • FTSE 250

    19,708.40
    -10.97 (-0.06%)
     

  • AIM

    754.90
    +0.21 (+0.03%)
     

  • GBP/EUR

    1.1672
    +0.0027 (+0.23%)
     

  • GBP/USD

    1.2523
    +0.0060 (+0.48%)
     

  • Bitcoin GBP

    50,985.52
    -2,187.02 (-4.11%)
     

  • CMC Crypto 200

    1,362.07
    -20.50 (-1.48%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    83.19
    +0.38 (+0.46%)
     

  • GOLD FUTURES

    2,339.60
    +1.20 (+0.05%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,991.45
    -97.25 (-0.54%)
     

  • CAC 40

    8,060.39
    -31.47 (-0.39%)
     
Property:

How to sell your home

Top tips from property investors

Why Adaptimmune Therapeutics Crushed the Market Today

Eric Volkman, The Motley Fool
·1-min read
Why Adaptimmune Therapeutics Crushed the Market Today

Adaptimmune Therapeutics (NASDAQ: ADAP), a biotech company active in the hot immunotherapy segment, was a high-temperature stock on Thursday. In advance of a June industry congress, Adaptimmune unveiled the results of its SPEARHEAD-1 study. This was undertaken to gauge the efficacy of its afamitresgene autoleucel, or afami-cel, to treat synovial sarcoma (cancer of soft tissue such as muscles or ligaments) and myxoid/round cell liposarcoma (MRCLS; a cancer of the cells that store fat).

Continue reading